Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021


      News provided by

      SWK Holdings Corporation

      Mar 28, 2022, 07:00 ET

      Share this article

      Share this article


      Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET

      Corporate Highlights

      • Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter as independent directors
      • Completed four transactions from December 2021 through March 2022, deploying $38.5 million
      • Received a $10.7 million cash payment from B&D Dental to successfully resolve long-running non-accrual position. Loan carried at $8.3 million
      • In December 2021, subsidiary Enteris received a $5.0 million milestone payment from Cara Therapeutics with SWK retaining $3.0 million
      • Enteris currently advancing six partner feasibility studies

      Finance Receivables Segment Update

      • As of December 31, 2021, non-GAAP tangible finance book value per share was $18.00, a 13.5% increase from December 31, 2020
      • Fourth quarter 2021 finance portfolio effective yield was 13.8%, flat year-over-year
      • Fourth quarter 2021 finance portfolio realized yield was 20.0%, a 340-bps year-over-year increase
      • Fourth quarter 2021 core finance receivables business adjusted non-GAAP net income was $6.9 million, which includes $0.6 million of extraordinary expenses
      • As of December 31, 2021, total investment assets were $189.7 million, a 10.7% decrease from December 31, 2020
      • For 2021 SWK's core finance receivables segment generated a 14.4% adjusted return on tangible book value

      DALLAS, March 28, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2021.

      "The fourth quarter concluded a strong 2021 for SWK's core specialty finance business as well as our Enteris subsidiary.  Our specialty finance portfolio delivered a 20.0% realized yield during the quarter as solid loan performance was buttressed by early loan payoffs and upside in our royalty portfolio," stated Winston Black, Chairman and CEO of SWK. "On the new deal origination front, 2022 is off to a strong start with our pipeline returning to historical levels. The turbulence in the capital markets has placed a premium on capital, and SWK is well positioned to capitalize on the market's volatility given our ample liquidity at quarter's end. We believe the four transactions closed over the past three months are an indication that SWK remains a leader in our market segment."

      Mr. Black concluded, "We are also pleased with the continued progress with our subsidiary, Enteris BioPharma, as it continues to pursue business development opportunities for its Peptelligence® and ProPerma® oral drug formulation technologies. Enteris is currently advancing six feasibility programs targeting therapeutic indications that include cancer, women's health, and disorders of the central nervous system. If the studies are successful and depending on our partner's R&D priorities, these feasibility agreements could advance to licensing agreements over the medium term, potentially providing new revenue streams for Enteris and SWK. Additionally, Enteris' contract manufacturing business is pursuing pharmaceutical customers to fill its expanded manufacturing facility."

      Fourth Quarter 2021 Financial Results

      For the fourth quarter 2021, SWK reported total revenue of $15.0 million, a 38% increase compared to $10.9 million for the fourth quarter 2020.  Finance Receivables segment revenue increased $1.4 million year-over-year to $9.5 million, with the increase consisting of a $3.5 million increase in fees and interest due to early payoff of two term loans during the quarter as well as revenue from new and existing loans, which was partially offset by a $2.2 million decrease in interest and fees earned on finance receivables that were repaid or paid down since the fourth quarter of 2020.  Pharmaceutical Development segment revenue increased $2.7 million year-over-year to $5.5 million.  During the fourth quarter of 2021, Enteris received a $5.0 million milestone from Cara Therapeutics with Enteris retaining $3.0 million of the milestone and the remaining $2.0 million reverting to Enteris' prior owner. 

      Income before taxes for the quarter was $8.4 million compared to $3.3 million for the same period the previous year. The year-over-year increase is due to a $2.7 million increase in income from our Pharmaceutical Development segment, a $1.4 million increase in revenue from our Finance Receivables segment, and a $2.0 million decrease in expenses. The decrease in expenses included a $2.5 million decrease in the change in fair value of the acquisition-related contingent consideration, a $1.7 million decrease in depreciation and amortization expenses related to the Enteris fixed and intangible assets, and a $0.8 million decrease in the change in fair value of our warrant assets and marketable investments. The decrease was offset by a $1.5 million increase in general and administrative expense, as well as an $0.8 million increase in our research and development expenses related to internal pipeline programs.

      For the fourth quarter 2021, non-GAAP adjusted net income was $9.5 million, an increase from $7.5 million from fourth quarter 2020.  Non-GAAP adjusted net income for the Finance Receivables segment was $6.9 million an increase from $6.4 million for the fourth quarter 2020.  Fourth quarter non-GAAP adjusted net income includes $0.6 million in extraordinary expenses from the Strategic Review process. 

      GAAP net income for the quarter ended December 31, 2021, totaled $6.3 million, or $0.49 per diluted share, compared to $4.6 million, or $0.36 per diluted share for the fourth quarter 2020.

      Income-producing assets (defined as finance receivables and corporate debt securities) totaled $181.7 million as of December 31, 2021. This is an 11.3% decrease compared with income-producing assets of $204.8 million as of December 31, 2020. Total investment assets, which include income-producing assets plus equity-linked securities, totaled $189.7 million as of December 31, 2021, compared to the December 31, 2020 total investment assets of $212.4 million.

      Tangible financing book value per share totaled $18.00 as of December 31, 2021, a 13.5% increase from $15.86 as of December 31, 2020. Management views tangible financing book value per share as a relevant metric to value the Company's core finance receivable business. Book value per share was $20.82 as of December 31, 2021, compared to $18.80 as of December 31, 2020.

      Tables detailing SWK's financial performance for the fourth quarter 2021 are below.

      Portfolio Status

      At the end of the fourth quarter 2021, the weighted average projected effective yield of 13.8% for the finance receivables portfolio, including non-accrual positions, was unchanged from the end of the fourth quarter of the previous year. The projected effective yield is the rate at which income is expected to be recognized pursuant to the Company's revenue recognition policies, if all payments are received pursuant to the terms of the finance receivables and excludes non-interest earning assets such as warrants and equity investments.

      For the fourth quarter 2021, the realized yield of the finance receivables portfolio was 20.0%, versus 16.6% for the same period the previous year. The realized yield is inclusive of all fees, including all realized unamortized fees, amendment fees, and prepayment fees, and is calculated based on the simple average of finance receivables at the beginning and end of the period. The realized yield is greater than the effective yield due to actual cash collections being greater than modeled.

      During the quarter SWK deployed $20.0 million in two structured debt transactions to MolecuLight and Biotricity, while SWK borrowers Misonix, DxTerity, and Celonova fully repaid their credit obligations. At quarter end, SWK had $7.2 million of unfunded commitments.   

      Total portfolio investment activity for the three months ended December 31, 2021, and 2020 was as follows (in thousands):



      Three Months Ended

      December 31,



      2021


      2020

      Beginning portfolio


      $                    206,247


      $                    187,039

      Early payoff


      (30,448)


      (3,686)

      Interest paid-in-kind


      252


      (229)

      Investment in finance receivables and marketable investments


      20,235


      30,401

      Loan discount and fee accretion


      (1,062)


      385

      Net unrealized gain (loss) on investments and warrant assets


      (124)


      639

      Principal payments received on investments


      (4,653)


      (1,276)

      Royalty (paydowns) accretion


      (1,006)


      (868)

      Warrant investments, net of cancellations


      175


      —

      Ending portfolio


      $                    189,616


      $                    212,405

      Portfolio Updates Post Year-End

      After the close of 2021, the Company closed three additional loans and advanced an additional $0.5 million to an existing borrower, deploying an additional $19.0 million

      • $6.5 million senior secured loan with Acer Therapeutics Inc. (NASDAQ: ACER)
      • $12.0 million in senior secured debt to Advanced Oxygen Therapy

      Adjusted Non-GAAP Net Income

      The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the three-month period ended December 31, 2021, and December 31, 2020. The table eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and equity securities, amortization of Enteris intangible assets and any non-cash impact on the remeasurement of contingent consideration.



      Three Months Ended

      December 31,



      2021


      2020

      Consolidated GAAP net income


      $                         6,327


      $                         4,644

      Add (subtract): income tax expense (benefit)


      2,102


      (1,338)

      Add: Enteris amortization expense


      543


      2,384

      Add (subtract): unrealized (gain) loss on warrants


      406


      (565)

      Add (subtract): unrealized gain on equity securities


      (282)


      (75)

      Add: strategic review committee expenses


      588


      —

      Add (subtract): (gain) loss on change in fair value of contingent consideration


      (140)


      2,436

      Adjusted income before income tax expense (benefit)


      $                         9,544


      $                         7,486

      Adjusted income tax expense (benefit)


      —


      —

      Non-GAAP consolidated net income


      $                         9,544


      $                         7,486

      In the table above, management has deducted the following non-cash items: (i) change in the fair-market value of equities and warrants, as mark-to-market changes are non-cash, (ii) income taxes, as the Company has substantial net operating losses to offset against future income, (iii) amortization expense associated with Enteris intangible assets, and (iv) (gain) loss on remeasurement of contingent consideration. Management has also deducted legal and board expenses associated with the Company's strategic review; management believes these expenses are not reflective of operational execution.

      Finance Receivables Adjusted Non-GAAP Net Income

      The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the Finance Receivable segment for the three-month period ended December 31, 2021, and December 31, 2020. The table eliminates Enteris operating (income) and loss. The adjusted income before income taxes is derived in the table above and eliminates income tax expense, non-cash mark-to-market changes on warrant assets and equity securities.



      Three Months Ended

      December 31,



      2021


      2020

      Adjusted income before income tax expense (benefit)


      $                         9,544


      $                         7,486

      Add (subtract): Enteris operating (income) loss, excluding amortization expense


      (2,625)


      1,086

      Adjusted Finance Receivables income before income tax expense (benefit)


      $                         6,919


      6,400

      Adjusted income tax expense (benefit)


      —


      —

      Non-GAAP Finance Receivables net income


      $                         6,919


      $                         6,400

      Conference Call Information

      SWK Holdings will host a conference call and live audio webcast on Monday, March 28, 2022, at 10:00 a.m. ET, to discuss its corporate and financial results for the fourth quarter 2021. Interested participants and investors may access the conference call by dialing either:

      (844) 378-6488 (U.S.)
      (412) 317-1079 (International)

      An audio webcast will be accessible via the Investors Events & Presentations section of the SWK Holdings' website: https://swkhold.investorroom.com/events. An archive of the webcast will remain available for 90 days beginning at approximately 11:30 a.m. ET, on March 28, 2022.

      Non-GAAP Financial Measures

      This release includes non-GAAP adjusted net income and non-GAAP finance receivable segment net income, which are metrics that are not compliant with generally accepted accounting principles in the United States (GAAP).

      Non-GAAP adjusted net income is adjusted for certain items (including (i) changes in the fair-market value of public equity-related assets and SWK's warrant assets as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, (iii) changes in the fair-market value of contingent consideration associated with the Enteris acquisition as these changes are non-cash, and (iv) depreciation and amortization expenses, primarily associated with the Enteris acquisition).

      In addition to the adjustments noted above, non-GAAP finance receivable segment net income also excludes Enteris operating losses.

      Tangible financing book value per share excludes the deferred tax asset, intangible assets, goodwill, Enteris PP&E, and contingent consideration associated with the Enteris transaction. Adjusted return on tangible financing book value is calculated by dividing finance receivables segment adjusted non-GAAP net income by Tangible financing book value.

      These non-GAAP measures may not be directly comparable to similar measures used by other companies in our industry, as other companies may define such measures differently. Management believes that these measures are useful to investors and management in understanding our ongoing operations and in analysis of ongoing operating trends and provides useful additional information relating to our operations and financial condition. These metrics should be considered in addition to, and not as a replacement for, the most comparable GAAP measure.

      About SWK Holdings Corporation

      SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris BioPharma, whose Peptelligence® and ProPerma™ drug delivery technologies create oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

      Safe Harbor Statement

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

      SWK HOLDINGS CORPORATION

      CONSOLIDATED BALANCE SHEETS

      (In thousands, except share data)


      December 31,


      2021


      2020

      Assets




      Current assets:




      Cash and cash equivalents

      $                42,863


      $                  3,008

      Interest and accounts receivable, net

      1,803


      1,911

      Marketable investments

      1,034


      1,210

      Other current assets

      1,727


      542

      Total current assets

      47,427


      6,671





      Finance receivables, net

      181,553


      204,491

      Marketable investments

      119


      241

      Cost method investment

      3,491


      3,491

      Deferred tax assets, net

      20,539


      27,491

      Warrant assets

      3,419


      2,972

      Intangible assets, net

      9,964


      13,453

      Goodwill

      8,404


      8,404

      Property and equipment, net

      5,779


      5,211

      Other non-current assets

      1,970


      1,476

      Total assets

      $              282,665


      $              273,901





      LIABILITIES AND STOCKHOLDERS' EQUITY




      Current liabilities:




      Accounts payable and accrued liabilities

      $                  5,087


      $                  3,652

      Revolving credit facility

      8


      $                11,758

      Total current liabilities

      5,095


      15,410





      Contingent consideration payable

      8,530


      16,900

      Other non-current liabilities

      1,804


      1,079

      Total liabilities

      15,429


      33,389





      Stockholders' equity:




      Preferred Stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and
      outstanding

      —


      —

      Common stock, $0.001 par value; 250,000,000 shares authorized; 12,836,133 and
      12,792,586 shares issued and outstanding at December 31, 2021 and 2020, respectively

      13


      13

      Additional paid-in capital

      4,431,719


      4,430,924

      Accumulated deficit

      (4,164,496)


      (4,190,425)

      Total stockholders' equity

      267,236


      240,512

      Total liabilities and stockholders' equity

      $              282,665


      $              273,901

      SWK HOLDINGS CORPORATION

      CONSOLIDATED STATEMENTS OF INCOME

      (In thousands, except per share data)


      Year Ended December 31,


      2021


      2020

      Revenues




      Finance receivable interest income, including fees

      $                39,310


      $                30,800

      Pharmaceutical development

      16,122


      5,903

      Other

      723


      9

      Total revenues

      56,155


      36,712

      Costs and expenses:




      Impairment expense

      —


      163

      Pharmaceutical manufacturing, research and development expense

      7,347


      4,268

      General and administrative

      13,620


      10,546

      Depreciation and amortization expense

      4,061


      12,091

      Change in fair value of acquisition-related contingent consideration

      (287)


      4,400

      Interest expense

      374


      455

      Total costs and expenses

      25,115


      31,923

      Other income (expense), net




      Unrealized net gain (loss) on warrants

      272


      (586)

      Unrealized net gain (loss) on equity securities

      1,839


      (591)

      Realized (loss) gain on sale of investments

      (140)


      53

      Income before income tax expense (benefit)

      33,011


      3,665

      Income tax expense (benefit)

      7,082


      (1,537)

      Consolidated net income

      $                25,929


      $                  5,202





      Net income per share




      Basic

      $                    2.03


      $                    0.40

      Diluted

      $                    2.02


      $                    0.40

      Weighted Average Shares




      Basic

      12,796


      12,852

      Diluted

      12,834


      12,862

      SWK HOLDINGS CORPORATION

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (In thousands)


      Year Ended December 31,


      2021


      2020

      Cash flows from operating activities:




      Consolidated net income

      $                25,929


      $                  5,202

      Adjustments to reconcile net income to net cash provided by operating activities




      Impairment expense

      —


      163

      Amortization of debt issuance costs

      49


      188

      Deferred income taxes

      6,952


      (1,711)

      Change in fair value of warrants

      (272)


      586

      Change in fair value of equity securities

      (1,839)


      591

      Loss (gain) on sale of investments

      140


      (53)

      Change in fair value of acquisition-related contingent consideration

      (287)


      4,400

      Loan discount and fee accretion

      (1,130)


      (1,983)

      Interest paid-in-kind

      (950)


      (2,145)

      Stock-based compensation

      1,163


      728

      Depreciation and amortization

      4,061


      12,091

      Changes in operating assets and liabilities:




      Interest and accounts receivable

      108


      643

      Other assets

      (1,788)


      (959)

      Accounts payable and other liabilities

      2,159


      1,527

      Net cash provided by operating activities

      34,295


      19,268





      Cash flows from investing activities:




      Cash received from settlement of warrants and equity securities

      1,875


      53

      Investment in finance receivables

      (42,350)


      (42,859)

      Repayment of finance receivables

      67,192


      11,752

      Corporate debt securities principal payments

      122


      62

      Purchases of property and equipment

      (1,078)


      (3,937)

      Other

      —


      (237)

      Net cash provided by (used in) investing activities

      25,761


      (35,166)





      Cash flows from financing activities:




      Net settlement for employee taxes on restricted stock and options

      (368)


      —

      Repurchases of common stock, including fees and expenses

      —


      (2,010)

      Net (payments on) proceeds from credit facility

      (11,750)


      11,758

      Payment of acquisition-related contingent consideration

      (8,083)


      (2,000)

      Net cash (used in) provided by financing activities

      (20,201)


      7,748





      Net increase (decrease) in cash and cash equivalents

      39,855


      (8,150)

      Cash and cash equivalents at beginning of period

      3,008


      11,158

      Cash and cash equivalents at end of period

      $                42,863


      $                  3,008





      Supplemental noncash flow activity:




      Warrants received in connection with finance receivables

      $                     175


      $                        79

      Fair value of common stock issued in lieu of employee cash bonuses

      $                        —


      $                        60

      Cash paid for interest

      $                     110


      $                     137

      Fair value of common stock received in connection with payoff of term loan

      $                     887


      $                        —

      SOURCE SWK Holdings Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.